Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkAntibody Response to COVID-19 Vaccination in Adults with Hematologic Malignant Disease

Publication: JAMA Oncology
Method: Retrospective study of 160 adults with hematologic malignant disease who were vaccinated with 1 of 3 COVID-19 vaccines (February through April 2021).
Results: Patients receiving B-cell-depleting immunotherapy may not gain adequate protection from vaccination and may still develop a potentially fatal infection.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form